3-甲氨基吡啶 | 18364-47-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-甲氨基吡啶
• 中文别名: 3-(甲氨基)吡啶
• 英文名称: N-methyl-N-(3-pyridyl)amine
• 英文别名: 3-methylaminopyridine；3-Methylaminopyridin；N-methylpyridin-3-amine；N-Methyl-3-pyridinamine
• CAS: 18364-47-1
• 化学式: C₆H₈N₂
• mdl: MFCD01418130
• 分子量: 108.143
• InChiKey: DBGFNLVRAFYZBI-UHFFFAOYSA-N

物化性质

• 熔点：
  201 °C
• 沸点：
  110°C/7mmHg(lit.)
• 密度：
  1.06g/ml
• 最大波长(λmax)：
  299nm(H2O)(lit.)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  6.1
• 安全说明：
  S36/37
• 危险类别码：
  R43
• 海关编码：
  2933399090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H317,H319
• 储存条件：
  室温下，在惰性气体的氛围中

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Methyl-3-pyridinamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H312: Harmful in contact with skin
H332: Harmful if inhaled
Causes skin irritation
H315:
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Methyl-3-pyridinamine
CAS number: 18364-47-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H8N2
Molecular weight: 108.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2810 Class: 6.1 Packing group: III
Proper shipping name: TOXIC, LIQUIDS, ORGANIC, N.O.S. OR TOXIC, LIQUIDS, ORGANIC, N.O.S. INHALA-
TION HAZARD, PACKING GROUP I, ZONE A OR B (N-Methyl-3-pyridinamine)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

3-甲氨基吡啶是一种有机中间体，可由3-氨基吡啶为原料先制备4-甲基-N-(吡啶-3-基)苯磺酰胺，然后再进行甲基化反应制备N,4-二甲基-N-(吡啶-3-基)苯磺酰胺，最后脱保护得到3-甲氨基吡啶。

制备过程 (1) 4-甲基-N-(吡啶-3-基)苯磺酰胺的制备

将3-氨基吡啶（14.1g，0.15mol）和对甲苯磺酸氯（30g，0.157mol）溶解于20mL吡啶中，在100℃下反应2小时。冷却后，将反应液倒入冰水中析出固体，经过抽滤和无水乙醇重结晶，得到白色固体36g，收率96.7%。

(2) N,4-二甲基-N-(吡啶-3-基)苯磺酰胺的制备

在40mL丙酮中加入4-甲基-N-(吡啶-3-基)苯磺酰胺（4.96g，20mmol）和碳酸钾（5.52g，40mmol），加热回流。将碘甲烷（5.67g，40mol）半小时内滴加到反应液中，继续回流反应2小时后冷却。抽滤并用丙酮洗涤固体，浓缩滤液得到棕色油状物4.7g，收率89.5%。

(3) 3-甲氨基吡啶的制备

将N,4-二甲基-N-(吡啶-3-基)苯磺酰胺（4.96g，18.9mmol）溶解于80%浓硫酸（20mL）中，在100℃下反应4小时。冷却后，用氨水调pH值至9，通过乙酸乙酯萃取、无水硫酸钠干燥和减压浓缩得到棕色油状物1.86g，收率91.0%。

反应信息

• 作为反应物：
  描述：

  3-甲氨基吡啶 在 哌啶 、 Co(dmgH)(dmgH₂)Cl₂ 、 2,4,5,6-四(9H-咔唑-9-基)异酞腈 作用下， 以 乙腈 为溶剂， 反应 72.0h， 以60%的产率得到3-氨基吡啶
  参考文献：
  名称：

  反向电子转移的最小化使得仲苯胺难以捉摸的 sp3 C−H 官能化

  摘要：

  苯胺是光诱导电子转移中最常用的一类底物。 N,N-二烷基衍生物能够通过氧化然后去质子化使 N 原子产生自由基 α。然而，由于快速反电子转移（BET），这种方法对于单取代苯胺来说难以捉摸。在这里，我们证明了在外源烷基胺存在的情况下使用光氧化还原催化可以最大限度地减少 BET。这种方法协同帮助苯胺 SET 氧化，然后加速随后的去质子化。通过这种方式，现在可以生成 α-苯胺烷基自由基，并且这些物质可以在一般意义上用于实现不同的 sp 3 C−H 官能化。

  DOI：

  10.1002/anie.202100051
• 作为产物：
  描述：

  N-(pyridin-3-yl)formamide 在 dimethyl sulfide borane 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 3-甲氨基吡啶
  参考文献：
  名称：

  通过甲酰化-硼烷：甲基硫化物还原，对官能化伯胺进行高效且通用的N-单甲基化

  摘要：

  在同一罐中用乙酸酐（AFA）对官能化的芳族伯胺和脂肪族伯胺进行甲酰化，然后将硼烷：甲硫醚还原，可以得到优异的分离收率的相应N-甲胺，且不受双烷基化的影响；该反应顺序甚至适用于弱碱性和位阻胺。

  DOI：

  10.1016/s0040-4039(00)87603-0

文献信息

• Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists
  申请人：Failli A. Amedeo

  公开号：US20060287522A1

  公开（公告）日：2006-12-21

  This invention provides pyrrolobenzodiazepine pyridine carboxamides selected from those of Formula (1), which act as follicle stimulating hormone receptor antagonists. The invention also provides pharmaceutical compositions and methods of treatment utilizing the compounds of Formulae (1) and (2).

  这项发明提供了从式（1）中选择的吡咯苯并二氮杂吡咯烷吡啶羧酰胺，其作为卵泡刺激素受体拮抗剂。该发明还提供了利用式（1）和（2）化合物的药物组合物和治疗方法。
• Tetracoordinate borates as catalysts for reductive formylation of amines with carbon dioxide
  作者：Xiaolin Jiang、Zijun Huang、Mohamed Makha、Chen-Xia Du、Dongmei Zhao、Fang Wang、Yuehui Li

  DOI：10.1039/d0gc01741h

  日期：——

  We report sodium trihydroxyaryl borates as the first robust tetracoordinate organoboron catalysts for reductive functionalization of CO2. These catalysts, easily synthesized from condensing boronic acids with metal hydroxides, activate main group element–hydrogen (E–H) bonds efficiently. In contrast to BX3 type boranes, boronic acids and metal-BAr4 salts, under transition metal-free conditions, sodium

  我们报告三羟基芳基硼酸钠作为第一个坚固的四配位有机硼催化剂，用于CO 2的还原功能化。这些催化剂很容易从硼酸与金属氢氧化物的缩合反应中合成，可以有效地活化主族元素氢键。与BX 3型硼烷，硼酸和金属-BAr 4盐相比，在无过渡金属的条件下，三羟基芳基硼酸钠对各种胺（包括带有官能团的胺）表现出较高的还原性N-甲酰化反应性（106例）例如酯，烯烃，羟基，氰基，硝基，卤素，MeS–，醚基等。催化具有挑战性的吡啶胺的甲酰化反应的性能过高，为使用传统的甲酰化试剂提供了一种有前途的替代方法。机理研究支持将静电相互作用作为Si / B–H活化的关键，从而使碱金属硼酸盐成为用于CO 2加氢硼化，加氢硅烷化和还原甲酰化/甲基化的通用催化剂。
• [EN] NOVEL PYRROLE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE PYRROLE
  申请人：UNIV LEICESTER

  公开号：WO2014195705A1

  公开（公告）日：2014-12-11

  There are provided inter alia compounds of formula (I), wherein R1, R2, R3, R4a and R4b are as defined in the specification and their use in therapy, especially in the treatment of bacterial (e.g. pneumococcal) infections.

  其中提供了式（I）的化合物，其中R1、R2、R3、R4a和R4b如规范中定义，并且它们在治疗中的用途，特别是在细菌感染（例如肺炎球菌感染）的治疗中。
• 具有生物活性的5,6,7,8-四氢吡啶并[3,4-d] 嘧啶化合物及其制备方法和应用
  申请人：河南师范大学

  公开号：CN104910158B

  公开（公告）日：2017-04-12

  本发明公开了一种具有生物活性的5,6,7,8‑四氢吡啶并[3,4‑d]嘧啶化合物及其制备方法和应用，属于具有抗肿瘤活性的化合物的合成技术领域。本发明的技术方案要点为：具有生物活性的5,6,7,8‑四氢吡啶并[3,4‑d]嘧啶化合物，具有如下结构：，其中R1为乙基甲酸酯基、乙胺甲基、甲胺甲酰基、二甲胺基甲酰基、吡啶‑3‑亚甲基胺基甲酰基、哌啶甲酰基或苯胺基甲酰基，R2为氢或苄基。本发明还公开了该具有生物活性的5,6,7,8‑四氢吡啶并[3,4‑d]嘧啶化合物的制备方法及其在制备抗乳腺肿瘤药物中的应用。本发明的制备过程工艺简单，易于控制，目标产物收率高且重复性好，制得的具有抗肿瘤活性的5,6,7,8‑四氢吡啶并[3,4‑d]嘧啶化合物均对乳腺癌细胞MCF‑7具有一定的抑制作用。
• Piperazine and homopiperazine compounds
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20030153556A1

  公开（公告）日：2003-08-14

  Compounds are provided having a piperazine or homopiperazine ring which are useful in the treatment of thrombosis.

  提供了具有哌嗪或同源哌嗪环的化合物，这些化合物在治疗血栓症方面很有用。

表征谱图